WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Sunday, June 7, 2020 
Add Press Release News | News Feeds Feeds | Email This News Email

Global Companion Diagnostics Partnering Deals 2010-2020: Trends, Players and Financials
Tuesday, May 26, 2020

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Companion Diagnostics Partnering Terms and Agreements 2010-2020" report has been added to's offering.

This report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

    --  Trends in Companion Diagnostics dealmaking in the biopharma industry
        since 2010
    --  Analysis of Companion Diagnostics deal structure
    --  Access to headline, upfront, milestone and royalty data
    --  Case studies of real-life Companion Diagnostics deals
    --  Access to Companion Diagnostics contract documents
    --  Leading Companion Diagnostics deals by value since 2010
    --  Most active Companion Diagnostics dealmakers since 2010

The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

The report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.

The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 450 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking.

    --  Chapter 1 provides an introduction to the report.
    --  Chapter 2 provides an overview of the trends in Companion Diagnostics
        dealmaking since 2010, including details of headline, upfront, milestone
        and royalty terms.
    --  Chapter 3 provides a review of the leading Companion Diagnostics deals
        since 2010. Deals are listed by headline value. Where the deal has an
        agreement contract published at the SEC a link provides online access to
        the contract.
    --  Chapter 4 provides a comprehensive listing of the top 25 most active
        companies in Companion Diagnostics dealmaking with a brief summary
        followed by a comprehensive listing of Companion Diagnostics deals
        announced by that company, as well as contract documents, where
    --  Chapter 5 provides a comprehensive and detailed review of Companion
        Diagnostics partnering deals signed and announced since Jan 2010, where
        a contract document is available in the public domain. Each deal title
        links via Weblink to an online version of the deal record and contract
        document, providing easy access to each contract document on demand.
    --  Chapter 6 provides a comprehensive and detailed review of Companion
        Diagnostics partnering deals signed and announced since Jan 2010. The
        Chapter is organized by specific Companion Diagnostics technology type.
        Each deal title links via Weblink to an online version of the deal
        record and where available, the contract document, providing easy access
        to each deal on demand.

A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.

Analyzing actual contract agreements allows assessment of the following:

    --  What are the precise rights granted or optioned?
    --  What is actually granted by the agreement to the partner company?
    --  What exclusivity is granted?
    --  What is the payment structure for the deal?
    --  How are sales and payments audited?
    --  What is the deal term?
    --  How are the key terms of the agreement defined?
    --  How are IPRs handled and owned?
    --  Who is responsible for commercialization?
    --  Who is responsible for development, supply, and manufacture?
    --  How is confidentiality and publication managed?
    --  How are disputes to be resolved?
    --  Under what conditions can the deal be terminated?
    --  What happens when there is a change of ownership?
    --  What sublicensing and subcontracting provisions have been agreed?
    --  Which boilerplate clauses does the company insist upon?
    --  Which boilerplate clauses appear to differ from partner to partner or
        deal type to deal type?
    --  Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

    --  20/20 GeneSystems
    --  Abbott Laboratories
    --  Abbvie
    --  Abcam
    --  AccuGenomics
    --  ADC Therapeutics
    --  Advanced Cell Diagnostics
    --  Advanced Nuclear Medicine Ingredients
    --  Aelan Cell Technologies
    --  Agilent Technologies
    --  Agios Pharmaceuticals
    --  Akili Interactive Labs
    --  Almac Diagnostics
    --  Amgen
    --  Amoy Diagnostics
    --  AmpTec
    --  Analytics Engines
    --  Angle
    --  Apogenix
    --  ArcherDX
    --  Arno Therapeutics
    --  Array Biopharma
    --  Astellas Pharma
    --  AstraZeneca
    --  Asuragen
    --  AVEO Oncology
    --  Bayer
    --  BeiGene
    --  Biocartis
    --  Biocept
    --  Biodesix
    --  Biogen
    --  Biognosys
    --  BioMarker Strategies
    --  bioMerieux
    --  Bliss Biopharmaceutical
    --  Blueprint Medicines
    --  Bonnie J. Addario Lung Cancer Foundation
    --  Bpifrance
    --  Bristol-Myers Squibb
    --  Bristol-Myers Squibb Pakistan
    --  CANbridge Life Sciences
    --  Cancer Genetics
    --  Caris Life Sciences
    --  Case Western Reserve University
    --  CDx Diagnostics
    --  Celgene
    --  Cellgen Diagnostics
    --  Cell Signaling Technology
    --  Centre for Imaging Technology Commercialization
    --  Centre National de la Recherche Scientifique
    --  Chembio Diagnostics
    --  Chugai Pharmaceutical
    --  Clevexel Pharma
    --  Cloud Pharmaceuticals
    --  Clovis Oncology
    --  Columbia University
    --  Companion Medical
    --  Core Diagnostics India
    --  Corgenix Medical
    --  Covance
    --  Daiichi Sankyo
    --  Dako
    --  Debiopharm
    --  Definiens
    --  DiamiR
    --  Diaxonhit
    --  Dimerix Biosciences
    --  Eli Lilly
    --  Enterome Bioscience
    --  Epic Sciences
    --  Eurofins Genomics
    --  Eutropics Pharmaceuticals
    --  Exact Sciences
    --  Exosome Diagnostics

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav SEOHost.Net: Negative Keywords are Critical for Successful Google Ads Campaigns | Jun 7, 2020
Nav TechSee Wins 'Best Use of AI' Accolade at the Annual Auggie Awards | Jun 7, 2020
Nav Quttera Announces Latest Enhancements to Website Malware Scanner API | Jun 7, 2020
Nav Curriculum Associates Updates i-Ready┬« to Meet Educators' Needs during School Closures and Beyond | Jun 7, 2020
Nav Key Vendor Insights in the Transport Layer Security Certificate Market 2020, Featuring Digicert, Entrust Datacard, Globalsign, Godaddy and Sectigo | Jun 7, 2020
Nav European Mobile Phone Accessories Market to Reach $47.18 Bn, by 2027, at 2.8% CAGR: Allied Market Research | Jun 7, 2020
Nav Impact Global Education Launches Domain, a flexible and affordable higher education solution | Jun 7, 2020
Nav U.S. Retail Recon Software Market to Reach $264.37 Mn, by 2027, at 11.8% CAGR: Allied Market Research | Jun 7, 2020
Nav Asahi Breweries Europe Group Selects GEP SMART(TM) Procurement Software And Goes Live With Source-To-Contract | Jun 7, 2020
Nav Bluestream Health and CommonWealth Purchasing Group Partner to Bring Much-Needed Virtual Care to the Nation's Underserved Population | Jun 7, 2020

Submit News | View More News View More News